Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs
NCT04302896 is a phase early 1 interventional trial sponsored by Rhonda Brand. As of 21 Nov 2026, it is completed. It studies Dolutegravir, Emtricitabine, Lamivudine and Tenofovir disoproxil in HIV and Medication Adherence. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 31 Aug 2020 and a primary completion date of 30 Sept 2021.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04302896 |
| Status | Completed |
| Phase | Phase Early 1 |
| Study type | Interventional trial |
| Lead sponsor | Rhonda Brand |
| Enrollment | 30 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | HIV and Medication Adherence |
| Drugs | Dolutegravir, Emtricitabine, Lamivudine and Tenofovir disoproxil |
| Start | 31 Aug 2020 |
| Primary completion | 30 Sept 2021 |
| Study completion | 30 Sept 2021 |
| Last update posted | 3 Mar 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Ken Ho, MD
University of Pittsburgh
Principal Investigator - Rhonda Brand, PhD
University of Pittsburgh
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hiv/aids Clinical Research Unit / University of Pittsburgh
Pittsburgh
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04302896
Each answer restates registry values shown on this page.
What is NCT04302896?
NCT04302896 is a phase early 1 interventional trial sponsored by Rhonda Brand. It studies Dolutegravir, Emtricitabine, Lamivudine and Tenofovir disoproxil in HIV and Medication Adherence.
Who leads NCT04302896?
The registry names Ken Ho, MD (principal investigator, University of Pittsburgh) and Rhonda Brand, PhD (study chair, University of Pittsburgh) as overall officials.
Where does NCT04302896 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04302896 study?
The registered drug and biological interventions are Dolutegravir, Emtricitabine, Lamivudine and Tenofovir disoproxil.
When did NCT04302896 end?
The registry lists a primary completion date of 30 Sept 2021 and a study completion date of 30 Sept 2021. The sponsor last updated the record on 3 Mar 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.